CGRP Therapies Reduced Migraine Days - Takeaways - MDSpire

CGRP Therapies Reduced Migraine Days

  • By

  • Andrea Surnit

  • May 20, 2026

Share

  • 1

    CGRP-targeted therapies reduced monthly migraine headache days by about 2 days compared to placebo in chronic migraine patients.

  • 2

    The systematic review included 43 trials with 14,725 adult patients, establishing high-certainty evidence for several CGRP therapies.

  • 3

    Fremanezumab and erenumab showed high-certainty evidence for achieving at least a 50% reduction in migraine days.

  • 4

    Galcanezumab likely reduced dropout rates due to any cause, while erenumab and atogepant increased risks of constipation and nausea.

  • 5

    The review highlighted the need for larger independent trials to assess long-term safety and effectiveness of CGRP therapies.

Original Source(s)

CGRP Therapies Reduced Migraine Days

  • by Andrea Surnit

  • May 20, 2026

Related Content

Can a Blood Count Predict Dementia?

Study explores a potential hematological risk marker using real-world data

  • May 20, 2026

  • 2 min
Asthma, Rhinitis Tied to Parkinson's Risk

A nationwide Korean cohort study found modestly higher Parkinson's disease incidence among patients with asthma or allergic rhinitis, with stronger associations observed among patients with greater allergic disease burden.

Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.